ArticleCNS neuroscience & therapeutics2025
Decorin Is a Newly Discovered Target of Akkermansia muciniphila in the Treatment of Sepsis-Associated Encephalopathy.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decorin Is a Newly Discovered Target of Akkermansia muciniphila in the Treatment of Sepsis-Associated Encephalopathy.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSepsis-associated encephalopathy (SAE) is a major contributor to mortality in septic patients, with its mechanisms being incompletely understood and effective therapies lacking. While the gut bacterium Akkermansia muciniphila (AKK) has shown beneficial effects in systemic infections, its specific role and mechanisms in SAE remain undefined.
methodsWe investigated the role of AKK in a murine model of sepsis induced by cecal ligation and puncture (CLP). Oral administration of AKK was confirmed via 16S rRNA sequencing. Mice underwent behavioral assessments to evaluate cognitive function. Hippocampal levels of pro-inflammatory cytokines were measured, and transcriptomic profiling was performed to identify key mediators. Functional analyses were conducted to delineate the role of the identified protein, Decorin (DCN), in neuronal survival, apoptosis, and autophagy. Simultaneously, we intervened in the expression of mouse DCN using AAV virus and further validated.
resultsOral AKK pretreatment was successfully enriched in the gut and significantly ameliorated CLP-induced cognitive deficits. It concurrently reduced hippocampal pro-inflammatory cytokine levels through a robust, DCN-independent anti-inflammatory pathway. Transcriptomics revealed that AKK treatment notably upregulated hippocampal DCN expression. Functional studies demonstrated that DCN contributed to AKK's neuroprotective effects by promoting autophagy and suppressing neuronal apoptosis, representing a distinct mechanism of action.
conclusionOur findings reveal a dual mechanism through which AKK mitigates SAE: (1) suppression of hippocampal inflammation via a DCN-independent pathway, and (2) DCN-dependent modulation of neuronal apoptosis and autophagy. This study establishes AKK as a promising microbial intervention for SAE and identifies DCN as a context-specific mediator of its neuroprotective effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.